J.Meulenberg, CEO of ViciniVax, participates in the 2018 BIO Europe convention, from November 5-7 in Copenhagen
Meet us at Bio Europe Spring 2018
March 07, 2018
J.Meulenberg, CEO of ViciniVax, attends the 2018 BIO Europe Spring convention, from March 12-14 in Amsterdam
ViciniVax announces last patient out in the Phase I study with immunotherapy Vvax001 ...
March 05, 2018
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018.
Meet us at Bio Europe 2017
November 03, 2017
J.Meulenberg, CEO of ViciniVax, attends the 2017 BIO Europe convention, from November 6-8 in Berlin
Phase I study initiated with Vvax001 in patients with a history of cervical intraepithelial neoplasia (CIN) 2 and 3 and cervical cancer.
Meet us at Cell Therapy Manufacturing and Gene Therapy Congress 2016
November 04, 2016
J.Meulenberg, CEO of ViciniVax, will present at the 2016 Cell Therapy Manufacturing and Gene Therapy Congress, from November 28-29 in Amsterdam, The Netherlands.
Meet us at Bio US 2016
June 03, 2016
J.Meulenberg, CEO of ViciniVax, attends the 2016 BIO International convention, from June 6-9 in San Francisco
Start of non-clinical safety studies
April 03, 2014
ViciniVax initiates Vvax001 non-clinical safety studies in UK and US.
